Isofol Medical AB
The answer first
Does Isofol Medical beat the market?
Yes, Isofol Medical has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 67% of Nordic stocks
- Quality72
- Value10
- Trend96
No. 42 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Isofol Medical keeps must grow about 8% a year for 10 years.
Max for seven days
Follow Isofol Medical with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Isofol Medical
Your first answer is free, no account needed.
Do you own Isofol Medical, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Isofol Medical and a few more. Free, no card.
Super Stock+46.4%In short
- Isofol Medical has risen 38.1% over the past year, including dividends.
- Overall, Isofol Medical ranks better than 67% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 97.9%. The price is 95.8% below its peak now.
What do analysts think of Isofol Medical?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 67% of Nordic stocks.
No. 42 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 79 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−66.9%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 134 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity3.6
- P/SPrice divided by salesnegative earnings
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 10 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+15.2%
- 6 months+36.2%
- 9 months+63.1%
- 12 months+38.1%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Isofol Medical
2 funds we follow own Isofol Medical. The share is how much of the fund the stock makes up.
- Sweden2
From the funds' latest known holdings.
About Isofol Medical
Isofol Medical AB is a company in healthcare, listed on Nasdaq Stockholm. By market value, Isofol Medical is number 64 of 137 companies in healthcare on Nasdaq Stockholm. Isofol Medical has not paid a dividend in the past twelve months. Of the three measures in the ranking, Isofol Medical is strongest on trend, better than 96% of Nordic stocks. The share trades in SEK. It has around 6 employees.
Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.


See the full analysis of Isofol Medical.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card